NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Question: 1 / 1820

What is a common risk associated with aromatase inhibitors and SERMS?

Hypoglycemia

Thromboembolic risk (clotting)

Aromatase inhibitors and selective estrogen receptor modulators (SERMs) are commonly used in the treatment of hormone-sensitive breast cancer. One of the common risks associated with these medications is an increased risk of thromboembolic events, which refers to the formation of blood clots within blood vessels that can lead to serious complications such as pulmonary embolism or stroke. This risk is important to monitor and manage in patients receiving these medications to prevent potentially life-threatening complications.

Options A, C, and D are not commonly associated with aromatase inhibitors and SERMs.

Get further explanation with Examzify DeepDiveBeta

Hypertension

Gastrointestinal issues

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy